Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes

Osteoarthritis and Cartilage

Volumn 11, Issue 4, 2003, Pages 290-298

  Largo, R ^a   Alvarez Soria, M A ^a   Diez Ortego I ^a   Calvo, E ^a   Sanchez Pernaute O ^a   Egido, J ^a   Herrero Beaumont, Gabriel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

COX 2; Glucosamine sulfate; Nuclear factor kappa B; Osteoarthritis; Prostaglandin E2

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLUCOSAMINE SULFATE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; PROTEIN P50; SYNAPTOTAGMIN;

ARTICLE; CARTILAGE CELL; CELL NUCLEUS; CELL STIMULATION; CELL TRANSFER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM;

EID: 0037385065     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(03)00028-1     Document Type: Article

References (37)

1. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
2. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997;11:817-34.
3. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopatogenesis of osteoarthritis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins 1969/1984/1997.
4. Pincus T. Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep 2001;3:524-34.
5. Abramson SB, Attur M, Amin AR, Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001;3:535-41.
6. Moskowitz RW. The role of antiinflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. Clin Exp Rheumatol 2001;19(6 Suppl 25):S3-8.
7. Amin AR, Attur MG, Abramson SB. Regulation of nitric oxide and inflammatory mediators in human osteoarthritis-affected cartilage: implication for pharmacological intervention. In: Rubanyi GM, Ed. The Pathophysiology and Clinical Applications of Nitric Oxide. Newark: Harwood Academic Publishers 1999;397-413.
8. Lotz M. Cytokines in cartilage injury and repair. Clin Orthop 2001;391(Suppl):108-15.
9. Vincenti MP, Brinckerhoff CE. Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1 beta. Arthritis Res 2001;3:381-8.
10. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
11. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3-6.
12. Altman RD, Lozada CJ. Practice guidelines in the management of osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):22-4.
13. Pavelka K, Gatterova J, Gollerova V, Urbanova Z, Sedlackova M, Altman RD. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying theraphy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage 2000;8:335-42.
14. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
15. Muller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar L. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:61-9.
16. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, et al. Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis. Arthritis Rheum 2001;44:351-60.
17. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 2001;166:5155-60.
18. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 2001;7:1171-82.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 1987;162:155-9.
20. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160:49-58.
21. Shlopov BV, Gumanovskaya ML, Hasty KA. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum 2000;43:195-205.
22. Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum 1983;26:975-83.
23. Setnikar I, Cereda R, Pacini MA, Revel L. Anti-reactive properties of glucosamine sulfate. Artzneimittelforschung 1991;41:157-61.
24. Setnikar I. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991;41:542-5.
25. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the function of neutrophils. J Leukoc Biol 2002;71:632-40.
26. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lacomi R, et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002;277:39343-9.
27. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun 1997;8:28-32.
28. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001;50:767-70.
29. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000;8:207-12.
30. Thomas B, Berembaum F, Humbert L, Bian H, Bereziat G, Crofford L, et al. Critical role of C/EBPδ and C/EBPβ factors in the stimulation of the cyclooxigenase-2 gene transcription by interleukin-1β in articular chondrocytes. Eur J Biochem 2000;267:6798-809.
31. Campbell IK, Gerondakis S, O'Donell K, Wicks IP. Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000;105:1799-806.
32. Johnson KA, Hulse DA, Hart RC, Kochevart D, Chu Q. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 2001;9:14-21.
33. Sandy JD, Gamett D, Thomson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
34. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998;6:427-34.
35. McCarty MF, Russell AL, Seed MP. Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis. Med Hypotheses 2000;54:798-802.
36. Bond M, Baker AH, Newby AC. Nuclear factor κB is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-7.
37. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993;3:538-50.